Scientech Research LLC Increases Holdings in Genmab A/S Sponsored ADR $GMAB

Key Points

• Scientech Research LLC increased its stake in Genmab A/S by 209.5% in Q1, holding 34,611 shares worth $678,000, signaling significant investor interest.
• Barclays PLC notably raised its holdings in Genmab by 1,072.8% during the last quarter, reflecting a broader trend of institutional investors accumulating shares.
• Analysts have a consensus rating of "Moderate Buy" for Genmab A/S, with an average target price of $37.60, indicating positive sentiment about the company's future performance.

Scientech Research LLC lifted its stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 209.5% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 34,611 shares of the company's stock after acquiring an additional 23,428 shares during the quarter. Scientech Research LLC's holdings in Genmab A/S were worth $678,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Headlands Technologies LLC boosted its stake in Genmab A/S by 1,525.0% during the 1st quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock valued at $31,000 after purchasing an additional 1,464 shares during the period. Caitong International Asset Management Co. Ltd increased its stake in Genmab A/S by 124.3% during the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock valued at $38,000 after acquiring an additional 1,070 shares during the period. Barclays PLC lifted its position in shares of Genmab A/S by 1,072.8% in the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock worth $52,000 after acquiring an additional 2,285 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Genmab A/S in the 4th quarter worth approximately $60,000. Finally, Brooklyn Investment Group lifted its position in shares of Genmab A/S by 729.3% in the 1st quarter. Brooklyn Investment Group now owns 4,246 shares of the company's stock worth $83,000 after acquiring an additional 3,734 shares during the period. Institutional investors own 7.07% of the company's stock.

Genmab A/S Stock Up 3.2%

Shares of GMAB traded up $0.88 during midday trading on Thursday, hitting $28.61. The company's stock had a trading volume of 1,514,643 shares, compared to its average volume of 1,354,207. Genmab A/S Sponsored ADR has a one year low of $17.24 and a one year high of $28.75. The company's fifty day simple moving average is $23.24 and its two-hundred day simple moving average is $21.57. The stock has a market capitalization of $18.36 billion, a price-to-earnings ratio of 16.22, a price-to-earnings-growth ratio of 1.62 and a beta of 0.93.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.39 by $0.15. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.The firm had revenue of $925.00 million for the quarter, compared to the consensus estimate of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS. On average, research analysts predict that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current year.

Wall Street Analyst Weigh In

GMAB has been the subject of several analyst reports. Zacks Research downgraded Genmab A/S from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 19th. Wall Street Zen raised Genmab A/S from a "hold" rating to a "buy" rating in a research note on Monday, July 28th. HC Wainwright lifted their price objective on Genmab A/S from $35.00 to $36.00 and gave the stock a "buy" rating in a research note on Friday, August 15th. Finally, Truist Financial boosted their target price on Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a research note on Tuesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Genmab A/S currently has a consensus rating of "Moderate Buy" and an average price target of $39.25.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.